{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:19:35Z","timestamp":1780525175019,"version":"3.54.1"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>Infants with congenital bilateral renal agenesis are at significant risk for morbidity and mortality, despite substantial and continuing advances in fetal and neonatal therapeutics. Infants with bilateral renal agenesis may episodically develop severe hypotension that can be refractory to traditional vasopressors. Synthetic angiotensin-II has been successfully used in adult and a few pediatric patients with refractory hypotension but has not been extensively studied in infants. We describe the use of angiotensin-II in treating refractory hypotension in a premature infant with congenital bilateral renal agenesis admitted to the NICU. Within 48 hours, he no longer required other vasopressors. Subsequently, angiotensin-II was gradually weaned and discontinued over 10 days and the patient was ultimately discharged from the hospital. This case demonstrates that angiotensin-II may be a helpful agent to treat refractory hypotension in infants with bilateral renal agenesis.<\/jats:p>","DOI":"10.1542\/peds.2023-062128","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:13:59Z","timestamp":1702628039000},"source":"Crossref","is-referenced-by-count":6,"title":["Angiotensin-II Use for Refractory Hypotension in an Infant With Bilateral Renal Agenesis"],"prefix":"10.1542","volume":"153","author":[{"given":"Sheila","family":"Razdan","sequence":"first","affiliation":[{"name":"aDivision of Neonatal and Developmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis S.","family":"Davis","sequence":"additional","affiliation":[{"name":"aDivision of Neonatal and Developmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tidmarsh","sequence":"additional","affiliation":[{"name":"aDivision of Neonatal and Developmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Hintz","sequence":"additional","affiliation":[{"name":"aDivision of Neonatal and Developmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Grimm","sequence":"additional","affiliation":[{"name":"bDivision of Pediatric Nephrology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie Y.","family":"Chock","sequence":"additional","affiliation":[{"name":"aDivision of Neonatal and Developmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"2024010102545223400_B1","volume-title":"Normal and Abnormal Development of the Kidney","author":"Potter","year":"1972"},{"issue":"2","key":"2024010102545223400_B2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/AOG.0000000000000339","article-title":"Successful in utero intervention for bilateral renal agenesis","volume":"124","author":"Bienstock","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"9-10","key":"2024010102545223400_B3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000526820","article-title":"Prenatal and early postnatal outcomes for fetuses with anatomic or functional renal agenesis","volume":"49","author":"Ogundipe","year":"2022","journal-title":"Fetal Diagn Ther"},{"issue":"8","key":"2024010102545223400_B4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.clinthera.2022.07.001","article-title":"Design and protocol of the Renal Anhydramnios Fetal Therapy (RAFT) Trial","volume":"44","author":"Atkinson","year":"2022","journal-title":"Clin Ther"},{"issue":"3","key":"2024010102545223400_B5","doi-asserted-by":"crossref","first-page":"e2022056570","DOI":"10.1542\/peds.2022-056570","article-title":"Kidney replacement therapy in low birth weight preterm newborns","volume":"150","author":"Sutherland","year":"2022","journal-title":"Pediatrics"},{"issue":"6","key":"2024010102545223400_B6","doi-asserted-by":"crossref","first-page":"e13532","DOI":"10.1111\/petr.13532","article-title":"Two infants with bilateral renal agenesis who were bridged by chronic peritoneal dialysis to kidney transplantation","volume":"23","author":"Sheldon","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2024010102545223400_B7","doi-asserted-by":"crossref","first-page":"S766","DOI":"10.1016\/j.ajog.2022.11.1307","article-title":"Neonatal survival after serial amnioinfusions for fetal bilateral renal agenesis: report from the RAFT trial","volume":"228","author":"Miller","year":"2023","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2024010102545223400_B8","doi-asserted-by":"crossref","first-page":"e0036","DOI":"10.1097\/CCE.0000000000000036","article-title":"Synthetic human angiotensin II in pediatric patients with vasodilatory shock: a report on two patients","volume":"1","author":"Bailey","year":"2019","journal-title":"Crit Care Explor"},{"issue":"5","key":"2024010102545223400_B9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/adc.82.5.388","article-title":"Angiotensin for septic shock unresponsive to noradrenaline","volume":"82","author":"Yunge","year":"2000","journal-title":"Arch Dis Child"},{"key":"2024010102545223400_B10","article-title":"Giapreza (angiotensin II): dosing and administration","author":"La Jolla Pharmaceutical Company"},{"issue":"5","key":"2024010102545223400_B11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit Care"},{"issue":"5","key":"2024010102545223400_B12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2024010102545223400_B13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II infusion for shock: a multicenter study of postmarketing use","volume":"159","author":"Wieruszewski","year":"2021","journal-title":"Chest"},{"issue":"12","key":"2024010102545223400_B14","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1053\/j.jvca.2022.07.022","article-title":"Angiotensin II - a brief review and role in severe SARS-COV-2 sepsis","volume":"36","author":"Car\u00e0","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"2024010102545223400_B15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13054-020-02862-1","article-title":"COVID-19 and the RAAS-a potential role for angiotensin II?","volume":"24","author":"Busse","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"2024010102545223400_B16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13019-021-01665-x","article-title":"A case report of an open aortic valve replacement followed by open adrenalectomy in a patient with symptomatic pheochromocytoma and critical aortic stenosis","volume":"16","author":"Feinstein","year":"2021","journal-title":"J Cardiothorac Surg"},{"issue":"2","key":"2024010102545223400_B17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1213\/XAA.0000000000001144","article-title":"Another role for angiotensin II?: vasopressin-refractory shock after pheochromocytoma resection: a case report","volume":"14","author":"Hylton","year":"2020","journal-title":"A A Pract"},{"issue":"7","key":"2024010102545223400_B18","first-page":"1135","article-title":"Re-evaluation of the plasma renin-angiotensin system in anephric patients","volume":"12","author":"Mizuno","year":"1990","journal-title":"Clin Exp Hypertens A"},{"issue":"3","key":"2024010102545223400_B19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00005344-199103000-00010","article-title":"Plasma angiotensins in anephric humans: evidence for an extrarenal angiotensin system","volume":"17","author":"Wilkes","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"2024010102545223400_B20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ndt\/gfu265","article-title":"Molecular regulation of the renin-angiotensin system in haemodialysis patients","volume":"30","author":"Kovarik","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2024010102545223400_B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.RES.41.4.17","article-title":"Plasma prorenin and renin in anephric patients","volume":"41","author":"Sealey","year":"1977","journal-title":"Circ Res"},{"issue":"2","key":"2024010102545223400_B22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00431-016-2820-9","article-title":"(Pro)renin and (pro)renin receptor expression during kidney development in neonates","volume":"176","author":"Terada","year":"2017","journal-title":"Eur J Pediatr"},{"key":"2024010102545223400_B23","article-title":"Blood pressure goals: is cerebral saturation the new mean arterial pressure","author":"McKim","journal-title":"Am J Perinatol"},{"issue":"5","key":"2024010102545223400_B24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jpeds.2013.12.042","article-title":"Hypotension in preterm neonates: low blood pressure alone does not affect neurodevelopmental outcome","volume":"164","author":"Alderliesten","year":"2014","journal-title":"J Pediatr"},{"issue":"10","key":"2024010102545223400_B25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1651-2227.2007.00439.x","article-title":"Noninvasive peripheral perfusion index as a possible tool for screening for critical left heart obstruction","volume":"96","author":"Granelli","year":"2007","journal-title":"Acta Paediatr"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062128\/1584772\/peds.2023-062128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062128\/1584772\/peds.2023-062128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T02:55:19Z","timestamp":1704077719000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/153\/1\/e2023062128\/196215\/Angiotensin-II-Use-for-Refractory-Hypotension-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,15]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2023-062128","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"article-number":"e2023062128"}}